美股A股
StockGist

PetMed Express, Inc.

PETSNASDAQ · Healthcare · Medical - Pharmaceuticals
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States.
$1.22-1.61%
报价 2026-11-06
市值
$26.4M
EV
$23M
PE (TTM)
–
预期 PE (FY2027)
17.4x
52 周区间距高点 -68.7%
$1.15$3.90

筛选结果

pipeline · 2026-11-06
Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
PETSPetMed Express, Inc.$26.4M-1.6%+1.0%27.6%–––
BDSXBiodesix, Inc.$69.4M-57.0%+29.1%82.5%–––
FBIOFortress Biotech, Inc.$61.7M+0.5%+31.4%64.5%1.0x–0.8x
RNTXRein Therapeutics Inc.$52.9M+0.3%–0%–––
MDAISpectral AI, Inc.$48M+8.0%+1.1%41.5%–––
TELATELA Bio, Inc.$37M+5.1%+7.8%67.8%–––
YI111, Inc.$25.5M-2.7%–5.7%–––
CTSOCytosorbents Corporation$15.1M+4.3%+8.0%71.6%–––
MDCXMedicus Pharma Ltd.$2.7M+2.2%–0%–––
同行中位数––+8.0%53%1.0x–0.8x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-06-30
Q1 2027
2026-03-31
Q4 2026
2025-12-31
Q3 2026
2025-09-30
Q2 2026
2025-06-30
Q1 2026
2025-03-31
Q4 2025
2024-12-31
Q3 2025
2024-09-30
Q2 2025
Revenue$41M$42.8M$40.7M$44.4M$51.2M$46.5M$53M$59.6M
Gross Margin27.6%16%23.3%28%23.7%40.8%28.1%29.1%
Operating Margin-15.2%-13.3%-25.7%-18.9%-13.4%-13%-0.8%0.9%
Net Income$-6.1M$-4.1M$-10.6M$-8.5M$-34.2M$-11.6M$-707,000$2.3M
Diluted EPS-0.28-0.19-0.5-0.41-1.65-0.56-0.030.11
Operating Cash Flow$-7.7M$-4.7M$-9.2M$-2.2M$-12.3M$7M$-1.2M$7.4M

研究材料

Filing 摘要
暂无 filing 摘要。
电话会纪要摘要
暂无纪要摘要。